Workshop A Tuesday, June 18

9:00 am -
Challenges and Prospects of Allogeneic CAR-T Cell Therapy
Workshop Leader: Zhongwei Xu, CSO, Bioceltech Therapeutics

Whilst most success in CAR-T therapies is currently seen in the autologous space we are seeing a drive for progress in allogeneic CAR-T therapies. Join us as we discuss: • Desgin for allo-CAR-T • Safety issue for Allo-CAR-T • GVHD/HVGD • Allo-CAR-T and its manufacture • Features and applications of uCAR-T and HLA-half matched donor CAR-T of “Beijing Approach”

Zhongwei Xu, CSO, Bioceltech Therapeutics

Workshop B Tuesday, June 18

1:00 pm -
Setting up and Managing Clinical Trials across Multiple Countries: The CRO Perspective
Workshop Leader: Martin Lachs, VP, Global Project Management, ICON

In the race to globalize CAR-TCR therapies there is a need to understand the varying global requirements needed to run effective trials.

Join us as we discuss:
• How to run a clinical program
• What are the different standards of care across the
globe
• Effective delivery of products
• Establishing appropriate primary endpoints for
engineered T cell trials
• Taking into account patient population used in study
• Patient identification and stratification
• Biomarkers of response
• Regualtory requirements for IND submission

Martin Lachs, VP, Global Project Management, ICON

With over 23 years’ experience in clinical development,
Martin has worked across a number of therapeutic areas
whilst specialising in oncology. He has been based in the UK
throughout his career.
Martin heads up ICON’s Oncology and Hematology Project
Management Group, lending operational and indication
expertise across a group of nearly 50 international project
management staff, dedicated to oncology drug development.